title: Variations in plasma apolipoprotein C-III levels are strong correlates of the triglyceride response to a high-monounsaturated fatty acid diet and a high-carbohydrate diet.
abstract: The objective of this study was to examine how a diet rich in carbohydrates (high-CHO) vs a diet rich in monounsaturated fatty acids (high MUFA) consumed ad libitum modulated plasma apolipoprotein C-III (apo C-III) levels and to examine the extent to which diet-induced changes in plasma apo C-III were associated with concurrent variations in plasma triglyceride (TG) levels. Forty-seven men (mean age, 35.7 +/- 11.4 years; body mass index, 29.0 +/- 5.1 kg/m2) were randomly assigned to either a high-CHO diet (CHO, 58%; fat, 26%; n = 23) or a high-MUFA diet (CHO, 45%; fat, 40%; MUFA, 22.5%; n = 24), which they consumed for 6 to 7 weeks. Fasting and postprandial lipemia after an oral fat load and fasting plasma apo C-III were measured at the beginning and at the end of the dietary intervention. Ad libitum consumption of the high-CHO diet induced a significant reduction in body weight (-2.6%, P < .0001), but had no impact on plasma apo C-III concentrations and on fasting and postprandial plasma TG levels. In contrast, ad libitum consumption of the high-MUFA diet also resulted in a significant reduction in body weight (-2.3%, P < .01) as well as in significant reductions in plasma apo C-III (-11%, P = .05) and fasting plasma TG (-17%, P < .01). Diet-induced variations in plasma apo C-III concentrations were correlated with changes in fasting and postprandial TG levels both in the high-CHO (r > 0.70, P < .001) and the high-MUFA groups (r > 0.42, P < .05). These results indicate that variations in plasma apo C-III levels are strong correlates of the fasting and postprandial plasma TG responses to high-MUFA and high-CHO diets.
authors.affiliation: Institute on Nutraceuticals and Functional Foods, Laval University, Ste-Foy, Québec, Canada G1K 7P4.
authors.forename: W Roodly
authors.initials: WR
authors.lastname: Archer
authors.forename: Sophie
authors.initials: S
authors.lastname: Desroches
authors.forename: Benoît
authors.initials: B
authors.lastname: Lamarche
authors.forename: Olivier
authors.initials: O
authors.lastname: Dériaz
authors.forename: Nancy
authors.initials: N
authors.lastname: Landry
authors.forename: Bénédicte
authors.initials: B
authors.lastname: Fontaine-Bisson
authors.forename: Jean
authors.initials: J
authors.lastname: Bergeron
authors.forename: Patrick
authors.initials: P
authors.lastname: Couture
authors.forename: Nathalie
authors.initials: N
authors.lastname: Bergeron
mesh_terms: D000328:Adult; D053305:Apolipoprotein C-III; D001056:Apolipoproteins C / Q000097:blood*; D008076:Cholesterol, HDL / Q000097:blood; D004040:Dietary Carbohydrates / Q000008:administration & dosage*; D004042:Dietary Fats, Unsaturated / Q000008:administration & dosage*; D006801:Humans; D008079:Lipoproteins, VLDL / Q000097:blood; D008297:Male; D008875:Middle Aged; D012044:Regression Analysis; D014280:Triglycerides / Q000097:blood*
chemical_list: D053305:Apolipoprotein C-III; D001056:Apolipoproteins C; D008076:Cholesterol, HDL; D004040:Dietary Carbohydrates; D004042:Dietary Fats, Unsaturated; D008079:Lipoproteins, VLDL; D014280:Triglycerides; C030106:very low density lipoprotein triglyceride